A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEARING PLEURAL CAVITY (INTRAPLEURAL) IN PATIENTS WITH INOPERABLE MALIGNANT PLEURAL MESOTHELIOMA

Trial Profile

A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEARING PLEURAL CAVITY (INTRAPLEURAL) IN PATIENTS WITH INOPERABLE MALIGNANT PLEURAL MESOTHELIOMA

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs HSV 1716 (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions
  • Sponsors Virttu Biologics
  • Most Recent Events

    • 08 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 08 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Jun 2017.
    • 08 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top